Related Experiment Video
Updated: Apr 26, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Antithrombotics in atrial fibrillation and coronary disease
Poonam Velagapudi1, Mohit K Turagam, Harsh Agrawal
1Department of Cardiovascular Medicine, University of Missouri-Columbia, School of Medicine, Columbia, MO, USA.
Insights
Atrial fibrillation (AF) and coronary artery disease (CAD) often coexist. This review examines antithrombotic strategies, including aspirin and novel anticoagulants, for patients with both conditions to prevent stroke and cardiovascular events.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation (AF) is a common heart arrhythmia.
- A significant percentage of AF patients also have coronary artery disease (CAD).
- Current guidelines lack clarity on optimal antithrombotic therapy for combined AF and CAD.
Purpose of the Study:
- To review evidence on antithrombotic strategies for patients with AF and CAD.
- To discuss the role of aspirin and novel oral anticoagulants in this population.
- To identify clinical scenarios where aspirin may be beneficial.
Main Methods:
- Literature review of existing studies and guidelines.
- Analysis of antithrombotic therapy options.
- Discussion of clinical evidence for aspirin and novel anticoagulants.
Main Results:
- Oral anticoagulation is standard for stroke prevention in AF.
- Antiplatelet therapy is recommended for CAD management.
- Evidence is limited for combined AF and CAD antithrombotic regimens.
- Novel anticoagulants add complexity to treatment combinations.
Conclusions:
- Optimal antithrombotic therapy for patients with both AF and CAD remains challenging.
- Further research is needed to guide treatment decisions.
- Aspirin may have a role in specific clinical situations for this patient group.
Abstract:
Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia and approximately 18-45% of AF patients have concomitant coronary artery disease (CAD). Several studies have demonstrated that oral anticoagulation is the mainstay of therapy for stroke prevention in AF. Similarly, antiplatelet therapy including aspirin and P2Y12 inhibitor is recommended in the management of acute coronary syndrome and stable CAD. Despite the high prevalence of CAD with AF, practice guidelines are scarce on the appropriate antithrombotic regimen due to lack of large-scale randomized clinical trials. The use of direct thrombin and factor Xa inhibitors for stroke prevention in AF has also complicated the possible combinations of antithrombotic therapies. This review aims to discuss the available evidence regarding aspirin as an antithrombotic strategy, the role of novel anticoagulants and the specific clinical situations where aspirin may be beneficial in patients with AF and CAD.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Venous Thrombosis III: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...